Journey Medical Corp (DERM)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $122.24M
Last updated: Nov 17, 2026 at 11:04 AM ET
Journey Medical Corp (DERM) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Journey Medical reported EPS of -$0.05, below the -$0.03 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
DERM's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
DERM Earnings Call
The latest DERM earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, DERM beat 16, missed 21 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $18.97M, up 7.6% from $17.63M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.05 | -$0.03 | -$0.08 - $0.03 | -66.67% | Miss | N/A | 4 | 0 up, 2 down | Nov 12, 2026 | $18.97M |
| Jun 30, 2026 | -$0.01 | -$0.01 | -$0.07 - $0.06 | 0.00% | In line | N/A | 4 | 1 up, 1 down | Aug 12, 2026 | $18.51M |
| Mar 31, 2026 | -$0.08 | -$0.09 | -$0.11 - -$0.05 | +11.11% | Beat | N/A | 4 | 0 up, 1 down | May 13, 2026 | $15.96M |
| Dec 31, 2025 | -$0.04 | -$0.04 | -$0.10 - -$0.01 | 0.00% | In line | -140.0% | 4 | 0 up, 1 down | Mar 25, 2026 | $16.08M |
| Sep 30, 2025 | -$0.09 | -$0.04 | -$0.08 - $0.01 | -125.00% | Miss | N/A | 4 | 0 up, 1 down | Nov 12, 2025 | $17.63M |
| Jun 30, 2025 | -$0.16 | -$0.10 | N/A | -60.00% | Miss | N/A | N/A | 0 up, 0 down | Aug 12, 2025 | $15.01M |
| Mar 31, 2025 | -$0.18 | -$0.24 | N/A | +25.00% | Beat | N/A | N/A | 0 up, 0 down | May 14, 2025 | $13.14M |
| Dec 31, 2024 | $0.10 | -$0.17 | N/A | +157.97% | Beat | N/A | N/A | 0 up, 0 down | Mar 26, 2025 | $13.62M |
| Sep 30, 2024 | -$0.12 | -$0.15 | -$0.21 - -$0.07 | +20.00% | Beat | -115.0% | 4 | 1 up, 0 down | Nov 12, 2024 | $14.63M |
| Jun 30, 2024 | -$0.17 | -$0.14 | -$0.17 - -$0.12 | -21.43% | Miss | N/A | 3 | 0 up, 0 down | Aug 12, 2024 | $14.86M |
| Mar 31, 2024 | -$0.53 | -$0.23 | -$0.26 - -$0.21 | -130.43% | Miss | N/A | 2 | 0 up, 0 down | May 13, 2024 | $13.03M |
| Dec 31, 2023 | -$0.12 | -$0.08 | -$0.09 - -$0.06 | -50.00% | Miss | N/A | 3 | 0 up, 0 down | Mar 21, 2024 | $15.26M |
| Sep 30, 2023 | $0.80 | -$0.15 | -$0.24 - -$0.07 | +633.33% | Beat | N/A | 2 | 0 up, 0 down | Nov 7, 2023 | $34.54M |
| Jun 30, 2023 | -$0.46 | -$0.33 | -$0.36 - -$0.31 | -39.39% | Miss | N/A | 2 | 0 up, 0 down | Aug 8, 2023 | $17.17M |
| Mar 31, 2023 | -$0.57 | -$0.45 | -$0.46 - -$0.42 | -26.67% | Miss | N/A | 3 | 0 up, 0 down | May 22, 2023 | $12.21M |
| Dec 31, 2022 | -$0.60 | -$0.47 | -$0.55 - -$0.37 | -27.66% | Miss | N/A | 3 | 0 up, 0 down | Mar 29, 2023 | $15.97M |
| Sep 30, 2022 | -$0.57 | -$0.40 | -$0.51 - -$0.20 | -42.50% | Miss | N/A | 3 | 0 up, 0 down | Nov 10, 2022 | $16.12M |
| Jun 30, 2022 | -$0.43 | -$0.26 | -$0.28 - -$0.24 | -65.38% | Miss | N/A | 3 | 1 up, 0 down | Aug 9, 2022 | $18.29M |
| Mar 31, 2022 | -$0.08 | -$0.31 | -$0.44 - -$0.18 | +74.19% | Beat | N/A | 2 | 0 up, 0 down | May 10, 2022 | $23.30M |
| Dec 31, 2021 | -$1.64 | -$0.41 | -$0.66 - -$0.28 | -300.00% | Miss | N/A | 3 | 0 up, 0 down | Mar 23, 2022 | $17.52M |
| Sep 30, 2021 | -$1.16 | -$0.87 | N/A | -33.33% | Miss | N/A | N/A | N/A | Nov 12, 2021 | $19.61M |
| Jun 30, 2021 | -$0.72 | -$1.30 | N/A | +44.62% | Beat | N/A | N/A | N/A | Sep 1, 2021 | $15.29M |
| Sep 30, 2019 | -$1.06 | -$1.30 | N/A | +18.46% | Beat | N/A | N/A | N/A | Nov 5, 2019 | $11.53M |
| Jun 30, 2019 | -$0.33 | -$0.95 | N/A | +65.26% | Beat | N/A | N/A | N/A | Aug 7, 2019 | $66.64M |
| Mar 31, 2019 | -$1.49 | -$1.62 | N/A | +8.02% | Beat | N/A | N/A | N/A | May 7, 2019 | $2.45M |
| Dec 31, 2018 | -$1.70 | -$1.91 | N/A | +10.99% | Beat | N/A | N/A | N/A | Feb 26, 2019 | $2.24M |
| Sep 30, 2018 | -$1.58 | -$1.63 | N/A | +3.07% | Beat | N/A | N/A | N/A | Nov 7, 2018 | $717000 |
| Jun 30, 2018 | -$0.57 | -$0.51 | N/A | -11.76% | Miss | N/A | N/A | N/A | Aug 6, 2018 | $39.08M |
| Mar 31, 2018 | -$1.42 | -$1.36 | N/A | -4.41% | Miss | N/A | N/A | N/A | May 3, 2018 | $299000 |
| Dec 31, 2017 | -$1.34 | -$1.22 | N/A | -9.84% | Miss | N/A | N/A | N/A | Feb 22, 2018 | $1.34M |
| Sep 30, 2017 | -$4.30 | -$1.12 | N/A | -283.93% | Miss | N/A | N/A | N/A | Nov 6, 2017 | $1.07M |
| Jun 30, 2017 | -$0.93 | -$0.89 | N/A | -4.49% | Miss | N/A | N/A | N/A | Aug 7, 2017 | $1.07M |
| Mar 31, 2017 | -$0.79 | -$0.89 | N/A | +11.24% | Beat | N/A | N/A | N/A | May 8, 2017 | $1.07M |
| Dec 31, 2016 | -$0.21 | -$0.80 | N/A | +73.75% | Beat | N/A | N/A | N/A | Feb 28, 2017 | $22.47M |
| Sep 30, 2016 | -$0.72 | -$0.72 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 7, 2016 | $119000 |
| Jun 30, 2016 | -$0.89 | -$0.86 | N/A | -3.49% | Miss | N/A | N/A | N/A | Aug 8, 2016 | N/A |
| Mar 31, 2016 | -$0.95 | -$0.94 | N/A | -1.06% | Miss | N/A | N/A | N/A | May 10, 2016 | N/A |
| Dec 31, 2015 | -$1.04 | -$0.95 | N/A | -9.47% | Miss | N/A | N/A | N/A | Mar 3, 2016 | $7.30M |
| Sep 30, 2015 | -$0.58 | -$0.77 | N/A | +24.68% | Beat | N/A | N/A | N/A | Nov 10, 2015 | $7.30M |
| Jun 30, 2015 | -$0.69 | -$0.75 | N/A | +8.00% | Beat | N/A | N/A | N/A | Aug 13, 2015 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.47, after -$0.72 the year before. It was -$8.96 for the year ended Dec 31, 2014, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.47 | N/A |
| Dec 31, 2024 | -$0.72 | N/A |
| Dec 31, 2023 | -$0.35 | N/A |
| Dec 31, 2022 | -$1.68 | N/A |
| Dec 31, 2021 | -$6.40 | N/A |
| Dec 31, 2018 | -$5.27 | N/A |
| Dec 31, 2017 | -$7.36 | N/A |
| Dec 31, 2016 | -$2.77 | N/A |
| Dec 31, 2015 | -$2.88 | N/A |
| Dec 31, 2014 | -$8.96 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,500 words across 9 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,515 | 9 | |
| 2026Q2 | Jun 30, 2026 | 4,456 | 9 | |
| 2026Q1 | Mar 31, 2026 | 5,050 | 9 | |
| 2025Q4 | Dec 31, 2025 | 5,274 | 9 | |
| 2025Q3 | Sep 30, 2025 | 5,260 | 9 | |
| 2025Q2 | Jun 30, 2025 | 3,415 | 8 | |
| 2025Q1 | Mar 31, 2025 | 4,057 | 9 | |
| 2024Q2 | Jun 30, 2024 | 3,634 | 8 |
2026Q3 Earnings Call
Opening remarks
Jaclyn Jaffe Senior Director of Corporate Operations Good afternoon, and thank you for participating in today's conference call. Joining me from Journey Medical's leadership team are Claude Maraoui, Co-Founder, President and Chief Executive Officer; Joseph Benesch, Chief Financial Officer; and Ramsey Alloush, Chief Operating Officer and General Counsel, who will participate in the Q&A portion of the call. During this call, management will be making forward-looking statements, including statements that address among other things, Journey Medical's expectations for future performance, operational results, financial condition and the receipt of regulatory approvals. Forward-looking statements involve risks and other factors that may cause actual results to differ materially from those statements. For more information about these risks, please refer to the risk factors described in Journey Medical's most recently filed periodic reports on Form 10-K and Form 10-Q, the Form 8-K filed with the SEC today and the company's press release that accompanies this call, particularly the cautionary statements in it. Today's conference call includes non-GAAP financial measures that Journey Medical believes can be useful in evaluating its performance. You should not consider this additional information in isolation or as a substitute for results prepared in accordance with GAAP. For a reconciliation of this non-GAAP financial measure to net loss, its most directly comparable GAAP financial measure, please see the reconciliation table located in the company's earnings press release. The content of this call contains time-sensitive information that is accurate only as of today, Thursday, November 12, 2026. Except as required by law, Journey Medical disclaims any obligation to publicly update or revise any information to reflect events or circumstances that occur after this call. It is now my pleasure to turn the call over to Claude Maraoui, Co-Founder, President and Chief Executive Officer of Journey Medical.
Claude Maraoui Co-Founder, President and CEO Thank you, Jaclyn. And good afternoon to everyone on the call today. We continued to make progress in the third quarter, delivering top-line growth and improved profitability during the period. Our total revenue grew by 8% in Q3, with net product sales increasing 11% year-over-year. Net sales of Emrosi were $9 million in the third quarter, up year-over-year and sequentially from the second quarter, driven by higher prescription volume, improving payer reimbursement and an increase in the number of dermatology writers prescribing the brand. We expect that these key metrics will continue to trend positively in the coming quarters. I am pleased to report that we achieved positive EBITDA for the second consecutive quarter. We remain focused on investing in our proven dermatology commercial infrastructure and driving top-line growth to advance the business toward becoming net earnings and cash flow positive. Emrosi prescriptions totaled approximately 40,000 in the third quarter, up from about 36,000 total prescriptions in the second quarter of this year.
Frequently Asked Questions About DERM
Did DERM beat earnings estimates last quarter?
No. Journey Medical reported EPS of -$0.05 for the quarter ended Sep 30, 2026, below the -$0.03 estimate by 66.67%.
What EPS do analysts expect from DERM next quarter?
The consensus EPS estimate for Journey Medical for the quarter ending Dec 31, 2026 is $0.00 from 6 analysts, with estimates from -$0.12 to $0.08.
How often does DERM beat earnings estimates?
Journey Medical beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -7.20%.
DERM pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors